VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.1811 +0.0039 (+2.20%)

Delayed Quote Updated: 2:22 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about VivoSim Labs, Inc. - Common Stock

< Previous 1 2 Next >

4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch

October 07, 2026

Via AB Newswire

Topics Animal Testing Artificial Intelligence

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

October 07, 2026

As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs

From VivoSim Labs, Inc.

Via GlobeNewswire

2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus

October 01, 2026

Via AB Newswire

2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!

September 28, 2026

Via AB Newswire

Topics Artificial Intelligence

VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs

September 28, 2026

Via AB Newswire

Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside

September 21, 2026

Via AB Newswire

Topics Government

VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem

September 21, 2026

Via AB Newswire

Topics Animal Testing

High-Impact Stocks DRK, VIVS, AEMD, GMG in the News

September 17, 2026

Via AB Newswire

Topics Artificial Intelligence Energy

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

September 16, 2026

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities

From VivoSim Labs, Inc.

Via GlobeNewswire

Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter

September 14, 2026

Via AB Newswire

Topics Artificial Intelligence

VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials

September 10, 2026

Via AB Newswire

VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity

September 02, 2026

Via AB Newswire

Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now

September 01, 2026

Via AB Newswire

Topics Artificial Intelligence Supply Chain

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

September 01, 2026

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans

From VivoSim Labs, Inc.

Via GlobeNewswire

IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook

September 01, 2026

Via AB Newswire

Topics Artificial Intelligence

VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology

August 26, 2026

Via AB Newswire

Topics Artificial Intelligence

Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now

August 26, 2026

Via AB Newswire

Topics Artificial Intelligence

VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum

August 25, 2026

Via AB Newswire

Topics Animal Testing Artificial Intelligence

VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum

August 17, 2026

Via AB Newswire

Topics Animal Testing Artificial Intelligence

VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

August 14, 2026

Via AB Newswire

Topics Animal Testing Artificial Intelligence

Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside

August 12, 2026

Via AB Newswire

Topics Artificial Intelligence

VivoSim Provides Financial and Listing Compliance Update

August 06, 2026

From VivoSim Labs, Inc.

Via GlobeNewswire

MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement

July 21, 2026

Via Investor Brand Network

Topics Animal Testing

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

July 21, 2026

Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market

From VivoSim Labs, Inc.

Via GlobeNewswire

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

July 16, 2026

From VivoSim Labs, Inc.

Via GlobeNewswire

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

July 15, 2026

From VivoSim Labs, Inc.

Via GlobeNewswire

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

June 29, 2026

VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)

From VivoSim Labs, Inc.

Via GlobeNewswire

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

April 28, 2026

VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results

From VivoSim Labs, Inc.

Via GlobeNewswire

VivoSim Announces Pricing of up to a $4 Million Public Offering

April 01, 2026

From VivoSim Labs, Inc.

Via GlobeNewswire

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

March 24, 2026

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity

From VivoSim Labs, Inc.

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.